Results 121 to 130 of about 10,714 (176)

The pathogenic E139D mutation stabilizes a non-canonical active state of the multi-domain phosphatase SHP2. [PDF]

Protein Sci
van Vlimmeren AE, Jiang Z, Karandur D, Applebaum Licht AT, Shah NH.   +4 more
europepmc   +1 more source

Erythrocyte membrane-encapsulated SZF nanocomposites for hyperuricemia therapy. [PDF]

Front Immunol
Liu W, Guan X, Wang L, Zhang C, Shen B, Zeng Y, Li D, Pu G, Hu J, Gao J.   +9 more
europepmc   +1 more source

RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. [PDF]

Mol Cancer Res
Baars B, Orive-Ramos A, Emmett MJ, Gaire B, Desaunay M, Kou Z, Li G, Adamopoulos C, Aaronson SA, Wang S, Sellers WR, Martin T, Gavathiotis E, Poulikakos PI.   +13 more
europepmc   +1 more source

A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors. [PDF]

NPJ Precis Oncol
Falchook G, Braganca Xavier C, Van Veenhuyzen D, Malhotra J, Sadeghi S, Kalebasty AR, Wood L, Rahman F, Li E, Pak Y, Khalil M, Spira AI, Sommerhalder D, Garrido-Laguna I, Hong DS.   +14 more
europepmc   +1 more source

Targeting SHP2 to reverse immune evasion and resistance to anti-PD-1 therapy in non-small cell lung cancer. [PDF]

Cell Commun Signal
Chen S, Wang D, Xiong D, Zhang L, Li K, Wang J, Ma X, Hu X, Zeng L, Xu J, Wu Y.   +10 more
europepmc   +1 more source

PD-1 suppresses CAR signaling by forming the inhibitory signalosome colocalizing to CAR microclusters. [PDF]

Commun Biol
Yoshida Y, Machiyama H, Wakamatsu E, Saito K, Takeuchi A, Nishikawa T, Matsushima R, Nishi W, Nishijima H, Kanno Y, Yokosuka T.   +10 more
europepmc   +1 more source

Antitumor effects of LPM5140276 and its potential combination with SHP2 inhibition in KRAS^G12D-mutant cancer. [PDF]

Front Pharmacol
Hu Z, Zou F, Zhao F, Yu P, Zhu H, Yu L, Wang W, Ye L.   +7 more
europepmc   +1 more source

Lung adenocarcinoma with KRAS-Q61H: clinicopathologic features, diagnostics, and the evolving treatment landscape. [PDF]

Front Oncol
Serafimidis I.
europepmc   +1 more source

Phosphatases in tumor cell immune escape: a perspective based on the camouflage, coercion, cytoprotection. [PDF]

Front Cell Dev Biol
Zhang C, Qiu X, Shi W, Zhu S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery

Medicinal Research Reviews, 2022
AbstractThe protein tyrosine phosphatase SHP2 encoded by PTPN11 is a promising therapeutic target for cancer therapy. The dynamic change of SHP2 between closed and open conformations under either physiological or pathological conditions provides opportunities to design SHP2 inhibitors for treating SHP2‐related diseases. To date, several SHP2 allosteric
Bin Yu, Yihui Song
exaly   +3 more sources